GlobeNewswire by notified

Innovating to Impact: Dentsu Unveils New Global Brand Proposition Drawing Upon 120 Year Heritage

Share

TOKYO, May 16, 2024 (GLOBE NEWSWIRE) -- Dentsu, today announced the launch of its new global, client-facing, brand proposition, "Innovating to Impact", marking a significant milestone in the company's storied 120-year plus history. The new go-to-market brand encapsulates dentsu's commitment to driving growth through innovation, leveraging the collective strengths of transformative creativity, media, data, and technology.

To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

Created through a collaborative effort of many dentsu teams around the world, "Innovating to Impact" reflects dentsu's dedication to delivering outcomes that not only drive business growth but also generate a positive effect on people, society and the world.

"Our new branding is a bold declaration of our unwavering commitment to innovate in pursuit of outcomes on behalf of our clients," said Hiroshi Igarashi, President & Global CEO, dentsu. "At dentsu, we are not content with simply following trends; we aim to set them. 'Innovating to Impact' is our promise to our clients, our incredible people and the communities we serve, that we will continue to push the boundaries of what's possible through experience and business transformation."

The launch is the next stage in dentsu’s mid to long-term strategy and its positioning as an integrated growth and transformation partner to the world’s leading organizations. Dentsu brings the best of both worlds to clients: individual global leadership brands that can deliver deep expertise, and the ability to tie those services together to deliver a multiplier effect for clients as dentsu.

A Dentsu Creative team, headed by Riccardo Fregoso, Chief Creative Officer Dentsu Creative Italy, led development of the tagline “Innovating to Impact”, along with a new brand manifesto. The design look and feel of the new brand was produced by the multi-award winning Dentsu Inc. team in dentsu Japan, led by Executive Creative Director, Yoshihiro Yagi, one of Japan’s most internationally awarded, art-based creatives.

“For over 120 years, innovation has been a core tenet of dentsu’s offering; it is in our DNA and within the very culture of our teams around the world. Innovation for dentsu is both an open mindset as well as a systematic approach, helping clients approach their business transformation in new ways,” commented Jean Lin, Global President – Global Practices, dentsu. “Dentsu is truly unique in the market, sitting at the convergence of marketing, technology and consulting. When we combine innovation with a laser focus on driving outcomes, we bring together the best of our capabilities to deliver integrated growth for brands who want something different from the traditional model.”

Dentsu's new brand will be further showcased at the Cannes Lions Festival in June 2024, with dentsu Beach House programming and design reflecting the principles and positioning of "Innovating to Impact".

For more information about dentsu and the new GTM brand, please visit: Innovating to Impact

Team credits:

Dentsu Creative Italy

Riccardo Fregoso, Chief Creative Officer
Stefano Battistelli, Executive Creative Director
Francesco Epifani, Executive Creative Director
Cristiana Bregni, Art Director
Santiago Cancela, Copywriter

Dentsu Inc., Japan

Yoshihiro Yagi, Executive Creative Director
Tsubasa Adachi, Creative Director
Haruko Tsutsui, Creative Director
Hiroyuki Kato, Art Director
Natsuki Tomoda, Art Director
Miyuki Ito, Copywriter
Mariko Fukuoka, Copywriter
Shintaro Murakami, Digital Technologist

About dentsu

Dentsu is an integrated growth and transformation partner to the world’s leading organizations. Founded in 1901 in Tokyo, Japan, and now present in over 145 countries and regions, it has a proven track record of nurturing and developing innovations, combining the talents of its global network of leadership brands to develop impactful and integrated growth solutions for clients. Dentsu delivers end-to-end experience transformation (EX) by integrating its services across Media, CXM and Creative, while its business transformation (BX) mindset pushes the boundaries of transformation and sustainable growth for brands, people and society.

Dentsu, Innovating to Impact.

Find out more:

www.dentsu.com
www.group.dentsu.com

Contact: 

Matt Cross
Email: matt.cross@dentsu.com

A photo accompanying this announcement is available at: 

https://www.globenewswire.com/NewsRoom/AttachmentNg/0b229c64-e587-4c92-80d2-8fb28b25ff1f

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Teva and Alvotech Announce SIMLANDI® (adalimumab-ryvk) Injection Now Available in the U.S.21.5.2024 02:25:00 CEST | Press release

SIMLANDI is the first interchangeable high-concentration, citrate-free biosimilar to Humira® REYKJAVIK, ICELAND & PARSIPPANY, NJ— Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) and Alvotech (NASDAQ: ALVO), today announced the availability of SIMLANDI (adalimumab-ryvk) injection in the U.S., as an interchangeable biosimilar to Humira for the treatment of adult rheumatoid arthritis, juvenile idiopathic arthritis, adult psoriatic arthritis, adult ankylosing spondylitis, Crohn’s disease, adult ulcerative colitis, adult plaque psoriasis, adult hidradenitis suppurativa and adult uveitis. “We are proud to make SIMLANDI available in the U.S. to patients and providers,” said Thomas Rainey, Senior Vice President, U.S. Market Access at Teva. “Biosimilars create opportunities for cost savings across the healthcare system, and SIMLANDI’s launch now offers the first citrate-free, high-concentration biosimilar to be designated interchangeable to Hu

IDEX Biometrics – Number of shares in Tranche 1 vs Tranche 2 in the private placement on 15 May 202420.5.2024 23:52:54 CEST | Press release

Reference is made to the stock exchange announcement by IDEX Biometrics ASA (the “Company”) on 15 May 2024 regarding a successful private placement of shares. By inadvertence, the announcement contained a slight error in the allocation of private placement shares between Tranche 1, as issued by the Board pursuant to an authorization to issue shares granted by the extraordinary general meeting dated 21 December 2023, and Tranche 2, to be issued subject to approval by an extraordinary general meeting to be called and scheduled for on or about 12 June 2024. The correct number of Tranche 1 shares is 27,940,213, and the correct number of Tranche 2 shares is 5,393,120, each having a par value of NOK 0.15, with a subscription price of NOK 1.65 per share in the private placement. Consequently, following the issuance of Tranche 1 shares, the Company's share capital is increased with NOK 4,191,031.95 from NOK 42,018,983.25 to NOK 46,210,015.20, and the Company will have 308,066,768 shares issued

INVNT™ ANNOUNCED AS SPONSOR AND CO-PRODUCER OF DISCOVERY STAGE AT SXSW SYDNEY® 202420.5.2024 23:00:00 CEST | Press release

Also named as an endorsed Creative Experiential Partner for the 2024 event Sydney, May 20, 2024 (GLOBE NEWSWIRE) -- INVNT™, the Experiential Disrupter Agency, has today been announced as the sponsor and co-producer of the SXSW Sydney 2024 Discovery Stage after a successful collaboration at last year’s inaugural event. For the second consecutive year, INVNT will bring its world-class expertise in production and innovative brand storytelling and “Challenge Everything” ethos to SXSW Sydney, where it will continue its legacy of hosting, curating and presenting the Discovery Stage and activating across the event’s key pillars of Tech & Innovation, Music, Games and Screen. Featured within the SXSW Sydney Tech & Innovation Expo, the 2024 Discovery Stage will play host to inspiring innovation leaders who are redefining industry norms and will be a place to explore the latest developments in technology and meet startup founders who are poised to disrupt the status quo. As last year’s Discovery

Nokia Corporation: Repurchase of own shares on 20.05.202420.5.2024 21:30:00 CEST | Press release

Nokia Corporation Stock Exchange Release 20 May 2024 at 22:30 EEST Nokia Corporation: Repurchase of own shares on 20.05.2024 Espoo, Finland – On 20 May 2024 Nokia Corporation (LEI: 549300A0JPRWG1KI7U06) has acquired its own shares (ISIN FI0009000681) as follows: Trading venue (MIC Code)Number of sharesWeighted average price / share, EUR*XHEL370,3933.56CEUX--BATE--AQEU--TQEX--Total370,3933.56 * Rounded to two decimals On 25 January 2024, Nokia announced that its Board of Directors is initiating a share buyback program to return up to EUR 600 million of cash to shareholders in tranches over a period of two years. The first phase of the share buyback program in compliance with the Market Abuse Regulation (EU) 596/2014 (MAR), the Commission Delegated Regulation (EU) 2016/1052 and under the authorization granted by Nokia’s Annual General Meeting on 4 April 2023 started on 20 March 2024 and ends by 18 December 2024 with a maximum aggregate purchase price of EUR 300 million. Total cost of tra

Press Release: Dupixent® late-breaking data from NOTUS confirmatory phase 3 COPD study presented at ATS and published in NEJM20.5.2024 20:15:00 CEST | Press release

Dupixent® late-breaking data from NOTUS confirmatory phase 3 COPD study presented at ATS and published in NEJM NOTUS results confirm landmark data from the phase 3 BOREAS study and show Dupixent significantly reduced exacerbations by 34% and improved lung function, compared to placebo, in uncontrolled chronic obstructive pulmonary disease (COPD) with evidence of type 2 inflammationData support the potential of Dupixent as the first new treatment approach in more than a decadeand first-ever targeted therapy for COPD Paris and Tarrytown, N.Y. May 20, 2024. Late-breaking data were presented from the NOTUS phase 3 study evaluating the investigational use of Dupixent® (dupilumab) as an add-on maintenance treatment in adults with uncontrolled COPD on maximal standard-of-care inhaled therapy (nearly all on triple therapy) and evidence of type 2 inflammation (i.e., blood eosinophils ≥300 cells per μL). The NOTUS study confirmed the positive results demonstrated in the landmark phase 3 BOREAS s

HiddenA line styled icon from Orion Icon Library.Eye